RT Journal Article
SR Electronic
T1 Impact of Baseline Body Mass Index on Immunotherapy Outcomes in Patients With Non-small-cell Lung Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5579
OP 5586
DO 10.21873/anticanres.17892
VO 45
IS 12
A1 KREJČÍ, DANIEL
A1 ŠUBRT, ADAM
A1 OPÁLKA, PETR
A1 KREJČÍ, JANA
A1 ŠIBALOVÁ, MONIKA
A1 SVATOŇ, MARTIN
A1 PÁLA, MILOSLAV
A1 TESAŘOVÁ, PETRA
A1 PAUK, NORBERT
YR 2025
UL http://ar.iiarjournals.org/content/45/12/5579.abstract
AB Background/Aim: Assessment of nutritional status plays an important role in treatment of patients with lung cancer. We conducted a real-world study to investigate the potential prognostic value of baseline body mass index (BMI) in patients with non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs).Patients and Methods: We retrospectively analysed data from 154 patients with advanced NSCLC treated with ICIs in the first or second line. Patients were stratified into two groups: BMI <25 kg/m2 and BMI ≥25 kg/m2. We investigated the impact of BMI on overall survival (OS), progression-free survival (PFS), time to treatment failure (TTF), and objective response rate (ORR) across the overall population and within prespecified subgroups defined by BMI.Results: Patients with BMI ≥25 kg/m2 (n=88) had a significantly better ORR compared to those with BMI <25 kg/m2 (n=66): 78.4% vs. 62.1%, p=0.03. There was no significant improvement in PFS, TTF or OS in the overall population. Subgroup analyses showed significant improvement in OS in favour of the BMI ≥25 kg/m2 group in non-smokers, in the subgroup receiving first-line immunotherapy, and in the subgroup with high expression of programmed cell death ligand 1. There was significant improvement in ORR in favour of the BMI ≥25 kg/m2 group in several subgroups. No significant improvements in PFS and TTF in subgroup analyses were observed.Conclusion: Our real-world study suggests that BMI might potentially act as a predictor for ORR in patients with advanced NSCLC treated with ICIs and should be considered in treatment decision-making. Additionally, we also observed a positive trend in OS among this group of patients.